C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test
At DNA Labs UAE, we offer the C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test at a cost of AED 4400.0. This test is used to diagnose and detect any mutations or variations in the C9orf72 gene that may increase the risk of developing ALS with FTD.
Test Details
The C9orf72 gene is associated with the development of amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). ALS is a progressive neurodegenerative disease that affects the nerve cells responsible for controlling voluntary muscle movement. FTD is a form of dementia that affects the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language. Mutations in the C9orf72 gene are the most common genetic cause of both ALS and FTD.
Our genetic test uses next-generation sequencing (NGS) technology to analyze the DNA sequence of the C9orf72 gene and identify any mutations or variations. This allows for early detection and potential intervention to slow the progression of the disease.
Test Components and Price
The C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test is priced at AED 4400.0. The test involves collecting a small sample of blood or saliva, or one drop of blood on an FTA card. The sample is then analyzed using NGS technology.
Report Delivery
Results from the test are typically available within 3 to 4 weeks. Once the report is ready, it will be delivered to the patient.
Test Type and Department
The C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test falls under the category of Neurological Disorders. The test is conducted by our team of experienced neurologists in the Genetics department.
Pre Test Information
Prior to the test, it is important to provide the clinical history of the patient who is going for the C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia NGS Genetic DNA Test. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia.
Conclusion
The C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test is a valuable tool for early detection and intervention in individuals at risk of developing ALS with FTD. By analyzing the DNA sequence of the C9orf72 gene, we can identify mutations or variations that may increase the risk of the disease. This information can be used to inform medical management and provide genetic counseling for individuals and their families.
| Test Name | C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with C9orf72 Gene Amyotrophic lateral sclerosis with frontotemporal dementia |
| Test Details |
The C9orf72 gene is associated with the development of amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). This genetic test uses next-generation sequencing (NGS) technology to analyze the DNA sequence of the C9orf72 gene and detect any mutations or variations that may increase the risk of developing ALS with FTD. ALS is a progressive neurodegenerative disease that affects the nerve cells responsible for controlling voluntary muscle movement. FTD is a form of dementia that affects the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language. Mutations in the C9orf72 gene are the most common genetic cause of both ALS and FTD. This genetic test can identify individuals who carry a mutation in the C9orf72 gene, allowing for early detection and potential intervention to slow the progression of the disease. The test involves collecting a small sample of blood or saliva and analyzing the DNA using NGS technology. Results are typically available within a few weeks and can be used to inform medical management and genetic counseling for individuals and their families. |
